Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.75 |
| ▸ | EDNRB | P24530 | 19/20 | 0.75 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | PDE4A | P27815 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907853 | 0.88 | EDNRA (0.59) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL6150890 | 0.86 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL29372653 | 0.82 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL803344 | 0.82 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL4142779 | 0.82 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL7048101 | 0.81 | EDNRA (0.68) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL6151306 | 0.80 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933770 | 0.80 | EDNRA (0.90) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL7252032 | 0.80 | EDNRA (0.68) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL8555870 | 0.79 | EDNRA (0.64) | EDNRAEDNRBABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080026061-A1 | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080026061-A1 | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide | ECE2, EDNRA, ECE1 | EDNRA 2/4885EDNRB 4/4885ABCC3 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.